Association of C-reactive protein and vitamin D deficiency with cardiovascular disease: A nationwide cross-sectional study from National Health and Nutrition Examination Survey 2007 to 2008

Qian Li1 | Zhenguo Dai2 | Yuze Cao1 | Lihua Wang1

1Department of Neurology, The Second Affiliated Hospital, Harbin Medical University, Harbin, China
2Department of Cardiology, The Second Affiliated Hospital, Harbin Medical University, Harbin, China

Abstract

Objectives: The association of C-reactive protein (CRP) and serum 25-hydroxyvitamin D [25(OH)D] and cardiovascular disease (CVD) remains unknown.

Methods: We performed a cross-sectional analysis on 3848 participants by using the data from the National Health and Nutrition Examination Surveys (2007 to 2008). CVD was defined as a compromise of stroke, myocardial infarction, heart failure, and coronary heart disease. High CRP was defined as ≥ 0.2 mg/dL, and vitamin D status were categorized as severe deficiency, <25 nmol/mL; deficiency, 25 to 49.9 nmol/mL; insufficiency, 50 to 74.9 nmol/mL; and normal, ≥75 nmol/mL. Statistical analysis was performed using logistic regression models.

Results: We found that both high CRP and low 25(OH)D levels were associated with CVD. Participants with high CRP levels and severe vitamin D deficiency had a higher likelihood of having CVD than those with neither risk factor (odds ratio = 2.69, 95% confidence interval = 1.45-4.98, \(P = .0017\)). In stratified analysis, a significant positive association between vitamin D level and CVD was observed only in the high CRP group. However, in the absence of high CRP, even with severe vitamin D deficiency, no association was found with an increasing risk of CVD (\(P = .6416\)).

Conclusion: Within a cross-sectional, nationally representative sample, these findings suggest that vitamin D status evaluation, or vitamin D supplement may be especially important for individuals with high CRP levels.

KEYWORDS
cardiovascular disease, C-reactive protein, NHANES, vitamin D

1 | INTRODUCTION

Cardiovascular disease (CVD) is considered traditionally as a major health concern that contributes to morbidity and mortality. Extensive and growing evidence suggested that inflammation is also a characteristic of this chronic process.\(^1\) Vitamin D is a fat-soluble steroid, which has been demonstrated to play a key role in modulating inflammatory cytokines and regulating immune cell activity.\(^2,3\) Emerging studies have indicated that vitamin D deficiency is linked to more inflammation and immune activation\(^4\) and can inversely be associated with a number of disease processes, including myocardial infarction.
C-reactive protein (CRP), a sensitive marker of inflammation, has been shown to be implicated in predicting incident CVD in multiple prospective epidemiological studies.\(^5\) One study suggested that the addition of measurement of CRP to screening based on lipid levels may provide an improved method of identifying women at risk for cardiovascular events.\(^6\) It is well documented that some of the CVDs that were benefit from medical treatment and lifestyle modification (regular physical activity, diet), are resulting from attenuation in inflammation.\(^1,7,8\) Observational studies showed an association between low serum vitamin D levels and increased cardiovascular risk,\(^7\) while vitamin D sufficiency appeared to have favorable effects on CVD.\(^10,11\) which may be partly associated with the immunomodulatory and anti-inflammatory properties of vitamin D. Vitamin D supplementation is found to be associated with a reduction in inflammatory marker levels in patients with osteoporosis\(^12\), heart failure\(^13\), but not in healthy persons.\(^14\) Randomized controlled trials (RCT) and evidence regarding whether vitamin D intake from foods or supplements prospectively associated with lower CVD risk have shown inconsistent results, with some trials suggesting a benefit and others concluding no effect on CVD.\(^15\)-\(^21\) There is possibility that the effect of vitamin D supplementation may vary by the status of CRP.

Therefore, in the present study, we tested the hypothesis of the combined association between 25(OH)D and CRP levels and CVD by using a representative sample of U.S. adults participating in the National Health and Nutrition Examination Survey (NHANES) 2007 to 2008.

2 | METHODS

2.1 | Data source and study population

We used data from NHANES conducted by the National Center for Health Statistics (NCHS), Centers for Disease Control and Prevention (CDC). Informed consent was obtained from all participants. The study is approved by the institutional review board of the National Center for Health Statistics. Data were pooled the cross-sectional data from the 2007 to 2008 NHANES cycle. In NHANES self-report data, participants were considered to have a history of cardiovascular disease if they responded “yes” to the question, “Has a doctor ever told you that you had congestive heart failure or coronary heart disease or heart attack or stroke?” CVD was defined as a compromise of stroke, myocardial infarction, heart failure, and coronary heart disease. The total population of NHANES 2007 to 2008 was 10,149. Participants were selected between 20 and 80 years of age (4464). Of the 4464 eligible subjects, 3848 had no missing data for all relevant covariates required for the analysis.

2.2 | Serum 25(OH)D and CRP concentration

For serum 25(OH)D measurements, the approaches transited to the liquid chromatography-tandem MS (LC-MS/MS) measurement procedure since NHANES 2007 and 2008. In addition, the LC-MS/MS allows for separate quantification of serum 25-hydroxyvitamin D\(_2\) [25(OH)D\(_2\)] (Isosciences, King of Prussia, Pennsylvania; Sigma, St. Louis, Missouri) and 25(OH)D\(_3\) (USP, Rockville, Maryland; Sigma).\(^22\) Serum 25(OH)D levels were then categorized as most of the previous clinical studies suggested, normal values (≥75 nmol/mL), insufficient (50-74.9 nmol/mL), deficient (25-49.9 nmol/mL), and severely deficient (<25 nmol/mL).\(^23,24\) Serum CRP was measured as described in the NHANES Laboratory Procedures Manual. CRP was measured using latex-enhanced nephelometry (Dade Behring Diagnostics Inc., Somerville, New Jersey), with high CRP levels defined as 0.20 mg/dL or greater. This process was then repeated substituting vitamin D deficiency for severe vitamin D deficiency referred to previous literature.\(^25\)

2.3 | Covariates

We chose covariates as potential confounding factors based on prior studies or based on their biological plausibility. The following covariates were included in our association analysis: age, sex, race/ethnicity, body mass index (BMI), family poverty income ratio (PIR), marital status, educational level, smoking status, alcohol consumption, physical activity, hypertension, diabetes, hypercholesterolemia, chronic kidney disease (CKD), and season of blood collection. Race/ethnicity was classified as non-Hispanic white, non-Hispanic black, Mexican American, and other. Marital status was classified as single/never married, married/live together, widowed, separated/divorced, and others. We categorized educational level as less than a high school education/primary education, a high school education/secondary education, and a college education. BMI was calculated as weight in kilograms divided by height in meters squared (kg/m\(^2\)). Height and weight were collected in the mobile examination center. The self-reported PIR, a marker of socioeconomic status used in multiple prior studies.\(^26\) Smoking status was classified as never, former, or current, which was constructed from responses to two questions: “Have you smoked at least 100 cigarettes in your life?” and “Do you now smoke cigarettes?” Participants who reported smoking every day or some days and had smoked at least 100 cigarettes were categorized as current smokers; respondents who reported currently not smoking but having smoked more than 100 cigarettes in the past were categorized as former smokers; and respondents who reported having smoked fewer than 100 cigarettes ever were categorized as non-smokers.\(^27\) Alcohol consumption was defined as having at least 12 drinks of any type of alcoholic beverage in the past year.\(^28\) For physical activity, the weekly number of minutes of moderate or vigorous activity, and the weekly number of minutes of vigorous activity were summed. Ideal health (active) was defined as ≥150 minutes/week of moderate or vigorous activity; intermediate health was defined as 1 to 149 minutes/week of moderate or vigorous activity; and poor health (inactive) was defined as 0 minute/week of moderate or vigorous activity.\(^28\) Hypertension was diagnosed if the participants reported being told by a physician that they have high blood pressure, were taking antihypertensive medications, or the average of three blood pressure readings was ≥140/90 mmHg.\(^28\) Hypercholesterolemia was diagnosed if total serum cholesterol ≥240 mg/dL or on cholesterol medications.\(^28\)
Participants were defined as having diabetes when a physician had ever told them that they had diabetes, excluding during pregnancy, with concurrent use of insulin or oral hypoglycemic medication, or a hemoglobin A1c ≥ 6.5%, non-fasting glucose ≥200 mg/dL, or fasting glucose ≥126 mg/dL.\(^2\) Dates of blood collections performed at physical examination visits were recorded and operationalized as November 1 to April 30 or May 1 to October 31. Glomerular filtration rate (GFR) was estimated based on the

| TABLE 1 | Characteristics of participants between 20 and 80 years of age stratified by cardiovascular disease (NHANES 2007-2008) |
|---------|------------------------------------------------------------------------------------------------------------------|
|         | No CVD | CVD | P-value |
| Number  | 3439 | 409 |          |
| 25(OH)D (nmol/mL) | (62.24 ± 25.22) | 60.73 ± 24.45 | .395 |
| Normal (≥75) | 978 (28.44) | 114 (27.87) | .887 |
| Insufficiency (50-74.9) | 1294 (37.63) | 152 (37.16) |          |
| Deficiency (25-49.9) | 996 (28.96) | 119 (29.10) |          |
| Severe deficient (<25) | 171 (4.97) | 24 (5.87) |          |
| CRP (mg/dL) | 0.43 ± (0.81) | 0.66 ± 1.34 | <.001 |
| <0.2 | 1716 (49.90) | 147 (35.94) | <.001 |
| ≥0.2 | 1723 (50.10) | 262 (64.06) |          |
| Age, year (means ± SD) | 48.65 ± 17.27 | 66.97 ± 12.29 | <.001 |
| Sex, males, n (%) | 1644 (47.80) | 250 (61.12) | <.001 |
| Race/ethnicity, Black, n (%) | 1666 (48.44) | 257 (62.84) | <.001 |
| BMI (kg/m²), (means ± SD) | 28.94 ± 6.57 | 30.18 ± 7.00 | <.001 |
| Family PIR, (means ± SD) | 2.60 ± 1.63 | 2.28 ± 1.47 | <.001 |
| Marital status, n (%) |          |          | <.001 |
| Married | 2125 (61.79) | 236 (57.70) |          |
| Widowed | 239 (6.95) | 82 (20.05) |          |
| Divorced/seperated | 503 (14.63) | 58 (14.18) |          |
| Single | 572 (16.63) | 33 (8.07) |          |
| Educational level, n (%) |          |          | <.001 |
| Less than a high school education/primary education | 994 (28.90) | 154 (37.65) |          |
| High school education/secondary education | 832 (24.19) | 98 (23.96) |          |
| College education | 1613 (46.90) | 157 (38.39) |          |
| Smoking status, n (%) |          |          | <.001 |
| Current smoking | 756 (21.98) | 84 (20.54) |          |
| Former smoking | 812 (23.61) | 179 (43.77) |          |
| Never smoking | 1871 (54.41) | 146 (35.70) |          |
| Alcohol consumption, n (%) | 2439 (70.92) | 276 (67.48) | .235 |
| Physical activity (minutes/week) |          |          | <.001 |
| No (0) | 1891 (54.99) | 282 (68.95) |          |
| Inactive (1-149) | 255 (7.41) | 24 (5.87) |          |
| Active (≥150) | 1293 (37.60) | 103 (25.18) |          |
| Hypertension, n (%) | 976 (28.38) | 297 (72.62) | <.001 |
| Diabetes mellitus, n (%) | 308 (8.96) | 129 (31.54) | <.001 |
| Hypercholesterolemia, n (%) | 1057 (30.74) | 250 (61.12) | <.001 |
| CKD, n (%) | 261 (7.59) | 122 (29.83) | <.001 |
| Season of blood collection, n (%) |          |          | <.001 |
| November 1 to April 30 | 1526 (44.37) | 136 (33.25) |          |
| May 1 to October 31 | 1913 (55.63) | 273 (66.75) |          |

Abbreviations: BMI, body mass index; CKD, chronic kidney disease; CRP, C-reactive protein; CVD, cardiovascular disease; PIR, poverty income ratio; 25(OH)D, 25-hydroxyvitamin D.

Values are presented as mean ± SD or number, (percentage of distribution).
Chronic Kidney Disease Epidemiology Collaboration (CKDEPI) equation CKD-EPI Equation. In these analyses, CKD was defined as estimated GFR less than 60 mL/min/1.73 m².

3 | STATISTICAL ANALYSIS

All analyses were performed with R (http://www.R-project.org). Differences in participant characteristics according to whether they had CVD were compared using independent-samples t tests (normal distribution) or Kruskal-Wallis rank sum test (non-normal distribution) for continuous measurements and χ² tests for categorical data or measurements.

Multiple logistic regression was used to determine the independent association between 25(OH)D status, with normal 25(OH)D as the reference category, and high and low CRP levels and CVD, respectively, after adjustment for demographic variables including age, sex, race/ethnicity, physical activity, educational level, marital status, family PIR, CKD, alcohol consumption, BMI, hypertension, diabetes mellitus, hypercholesterolemia, and season of specimen collection (6-month period). Two additional logistic regression models were used to evaluate the association of vitamin D and CRP with CVD after controlling for the same confounders.

Finally, logistic regression was used to evaluate the association between vitamin D status and CVD after stratifying participants according to high and low CRP status. The association between CRP status and CVD was also analyzed using logistic regression after stratification according to vitamin D status (severe deficiency, deficiency, insufficient, normal) and their interactions were tested. A P-value of <.05 was considered statistically significant.

4 | RESULTS

Of the 10,149 eligible subjects from NHANES (2007-2008), 3848 had no missing data for all relevant covariates required for the analyses (n = 3439 in non-CVD, n = 409 in CVD). The baseline characteristics of the subjects in the analytic sample were separated by CVD and non-CVD were shown in Table 1. The percentage of subjects with CVD was higher in those with lower levels of vitamin D, yet this did not reach a statistically significant (P = .887). Participants with CVD had a significantly greater frequency of high CRP than those without (64.06% vs 50.10%; P < .001). On average, individuals with CVD were more likely to be older, male, non-Hispanic black, a former smoker, less educated, and less physically active than participants without CVD. Moreover, they had higher BMI, lower family PIR; they were less likely to be married and non-smokers, and had more traditional CVD risk factors, such as hypertension, diabetes mellitus, hypercholesterolemia, and history of chronic kidney disease.

Table 2 shows the OR of cardiovascular events according to the level of 25(OH)D and CRP. Subjects with severe vitamin D deficiency were more likely to have CVD (odds ratio [OR] = 1.90, 95% confidence interval [CI] = 1.06, 3.40, P = .0317). Those with insufficient vitamin D or vitamin D deficiency were also more likely to have CVD, yet these findings did not reach statistical significance (P > .05). When 25(OH)D level was entered into the model as a pseudo-continuous variable, the likelihood of having CVD increased with decreasing levels of 25(OH)D (P = .0128). Participants with high CRP had a significantly increased chance to have CVD than those with low CRP (OR = 1.47, 95% CI = 1.14-1.89, P = .0029).

Model adjusted for age, sex, race, physical activity, educational level, marital status, family poverty income ratio, body mass index, season of blood collection, smoking status, and alcohol drinking, hypertension, diabetes mellitus, hypercholesterolemia, and history of chronic kidney disease.

5 | DISCUSSION

In the present study, we performed a large cross-sectional study of nationally representative sample of adults >20 years of age by using continuous NHANES (2007-2008). In addition to being a disease of modified lipoproteins accumulation in the artery wall, inflammation is...
also an additional key aspect of this disease process.32 In this study, we chose CRP as such a marker of inflammation, and confirmed that individuals with high CRP had a higher likelihood of CVD (Table 2). Lower vitamin D status was previously found to be associated with increased risk and unfavorable outcome of CVD,33,34 herein, our results revealed that individuals with both high CRP and severe vitamin D deficiency had 2.69 times the likelihood for experiencing CVD, which was higher than those with neither of them (Table 3). In terms of clinical application, the addition of the measurement of CRP to screening based on vitamin D levels may thus provide a simple and inexpensive method to improve risk prediction for cardiovascular events.

In the stratified analysis of the current study, we found that in the absence of inflammation, even having severe vitamin D deficiency was not associated with increasing likelihood of CVD, but participants with high CRP without severe vitamin D deficiency were still more likely to have CVD (Table 3). The findings indicate that the link between vitamin D and CVD depends on the inflammation status. Thus, recommendations to improve vitamin D status on the basis of monitoring CRP levels may be of benefit to reduce the burden of

### Table 3

| Effect | n   | OR (95% CI) | P-value |
|--------|-----|-------------|---------|
| Combination of vitamin D level (deficiency/no deficiency) and CRP level (low/high) | | | .0006 |
| No vitamin D deficiency and low CRP | 1314 | 1.00 | |
| Vitamin D deficiency and low CRP | 549 | 1.19 (0.77, 1.86) | .4365 |
| No vitamin D deficiency and high CRP | 1224 | 1.38 (1.02, 1.86) | .0360 |
| Vitamin D deficiency and high CRP | 761 | 2.01 (1.39, 2.89) | .0002 |

Combination of vitamin D level (severe deficiency/no severe deficiency) and CRP level (low/high)

| Effect | n   | OR (95% CI) | P-value |
|--------|-----|-------------|---------|
| No severe vitamin D deficiency and low CRP | 1790 | 1.00 | |
| Severe vitamin D deficiency and low CRP | 73 | 0.74 (0.21, 2.63) | .6416 |
| No severe vitamin D deficiency and high CRP | 1863 | 1.42 (1.10, 1.84) | .0068 |
| Severe vitamin D deficiency and high CRP | 122 | 2.69 (1.45, 4.98) | .0017 |

### Table 4

Cross-sectional association between vitamin D level and cardiovascular disease, according to CRP level, in the National Health and Nutritional Examination Survey 2007 to 2008 (n = 3848)

| Vitamin D status (nmol/mL) | CRP ≥ 0.2 mg/dL (n = 1985) | CRP < 0.2 mg/dL (n = 1863) |
|---------------------------|----------------------------|----------------------------|
|                           | Model 1 OR (95% CI) | P-value | Model 2 OR (95% CI) | P-value | Model 3 OR (95% CI) | P-value |
| Normal (≥ 75) (n = 495)  | 1.00 | 1.00 | 1.00 |
| Insufficiency (50-74.9) (n = 729) | 1.20 (0.83, 1.74) | .3394 | 1.09 (0.75, 1.60) | .6431 | 1.15 (0.78, 1.72) | .4803 |
| Deficiency (25-49.9) (n = 639) | 1.67 (1.12, 2.49) | .0122 | 1.37 (0.91, 2.08) | .1332 | 1.45 (0.94, 2.24) | .0908 |
| Severe deficient (<25) (n = 122) | 2.42 (1.28, 4.56) | .0063 | 1.90 (0.99, 3.66) | .0533 | 2.43 (1.23, 4.82) | .0110 |

Abbreviations: BMI, body mass index; CI, confidence interval; CRP, C-reactive protein; OR, odds ratio; 25(OH)D, 25-hydroxyvitamin D.

Model adjusted for age, sex, race, physical activity, educational level, marital status, family PIR, body mass index, season of blood collection, smoking status, and alcohol drinking, hypertension, diabetes mellitus, hypercholesterolemia, history of chronic kidney disease.

LI ET AL. CLINICAL CARDIOLOGY WILEY
CVD. Additional well-designed clinical studies may be warranted to
determine whether individuals with high CRP levels are especially
important for vitamin D to exert the protective effect against CVD.

There are evidence supporting the potential association of vitamin
D and CRP with CVD observed in this study. Inflammatory state
manifested by high CRP levels may lead to low 25(OH)D levels, and
reduction of vitamin D contributes to the dysregulation of immune
and inflammatory responses, such as respiratory infections and psoriasis.3,35,36 Moreover, studies in animal models and cell culture showed
that vitamin D treatment could arrest nuclear factor κB translocation
and suppress its activity,37 and could produce anti-inflammatory
effects by modulating immune cells and signaling pathways.3

Although the present study is a cross-sectional observational
study, our results have the advantage of containing a large and nation-
ally representative sample size to better estimate association of high
CRP and low vitamin D with CVD, giving credence to the external
validity of the results. Moreover, the NHANES allowed us to adjust
for numerous potential confounders in the analysis. Furthermore,
serum 25(OH)D concentrations were measured using a LC-MS/MS
measurement procedure developed by the CDC, which is considered
more analytically accurate, precise, and specific than immunoassay
methods.22

However, in interpreting the results of this study, some limitations
in the present study still exist due to its intrinsic cross-sectional
nature. First of all, for the sake of data integrity, we only studied one
NHANES cycle from 2007 to 2008. Second, the information selected
on vitamin D, CRP, and CVD was collected at the same point, our
study could not ensure to examine a temporal relation between vita-
min D and CRP. Third, the study is unable to test the risk of decreased
serum vitamin D and/or increased CRP concentrations for the inci-
dence of CVD. At last, data on the diets enriched with vitamin D,
including supplements, that could modify 25(OH)D blood levels were
not available for analysis.

6 | CONCLUSIONS

In conclusion, although our study is a cross-sectional study, we
believe that our findings are of great public health significance. Sub-
jects with vitamin D deficiency and CRP levels ≥0.2 mg/dL represent
a higher chance to have CVD. Vitamin D was significantly associated
with CVD only in those with high CRP, this statistical evidence sup-
ports the view that the burden of CVD in individuals with high CRP
may be reduced by improving serum 25(OH)D concentrations. Future
RCTs should focus on the effects of vitamin D supplements on CVD
by comparing individuals with high CRP and those with low CRP.

ACKNOWLEDGMENTS

We would like to acknowledge the National Health and Nutrition
Examination Survey (NHANES) for providing the dataset for analysis.
We thank Di Wang from Canada for English-language editing of this
manuscript. This work was supported by the National Natural Science
Foundation of China (Grant nos. 81820108014, 81771361,
81571166).

CONFLICT OF INTEREST

The authors declare no potential conflict of interests.

ORCID

Lihua Wang https://orcid.org/0000-0003-3946-4032

REFERENCES

1. Libby P. Inflammation and cardiovascular disease mechanisms.
Am J Clin Nutr. 2006;83(2):456S-460S.
2. Guillot X, Semerano L, Saldenberg-Kermanac’h N, Falgarone G,
Boissier M-C. Vitamin D and inflammation. Joint Bone Spine.
2010;77(6):552-557.
3. Colotta F, Jansson B, Bonelli F. Modulation of inflammatory and
immune responses by vitamin D. J Autoimmun. 2017;85:78-97.
4. Jiménezsousa MA, Martinez I, Medrano LM, Femándezrodrigz A,
Resino S. Vitamin D in human immunodeficiency virus infection: influ-
ence on immunity and disease. Front Immunol. 2018;Mar 12;9:458.
5. Ridker PM. Clinical application of C-reactive protein for cardiovas-
cular disease detection and prevention. Circulation. 2003;107(3):
363-369.
6. Ridker PM, Hennekens CH, Buring JE, Rifai N. C-reactive protein
and other markers of inflammation in the prediction of cardiovas-
dular disease in women. N Eng J Med. 2000;342(12):836-843.
7. Lopez-Garcia E, Schulze MB, Fung TT, et al. Major dietary patterns
are related to plasma concentrations of markers of inflammation and
endothelial dysfunction. Am J Clin Nutr. 2004;80(4):1029-1035.
8. Wannamethee SG, Lowe GDO, Whincup PH, Rumley A, Walker M,
Lennon L. Physical activity and hemostatic and inflammatory variables
in elderly men. Circulation. 2002;105(15):1785-1790.
9. Demer LL, Hsu JJ, Tintut Y. Steroid hormone vitamin D: implications
for cardiovascular disease. Circ Res. 2018;122(11):1576-1585.
10. Zittermann A, Schleithoff SS, Koerfer R. Putting cardiovascular dis-
ease and vitamin D insufficiency into perspective. Br J Nutr. 2005;94
(04):483-492.
11. Holick MF, Holick MF. Sunlight and vitamin D for bone health and
prevention of autoimmune diseases, cancers, and cardiovascular dis-
ease. Am J Clin Nutr. 2005;80(6 Suppl):1678S-1688S.
12. Inanir A, Özoran K, Tutkak H, Mermerci B. The effects of calcitriol
therapy on serum interleukin-1, interleukin-6 and tumour necrosis
factor-α concentrations in post-menopausal patients with osteopor-
sis. J Int Med Res. 2004;32(6):570-582.
13. Schleithoff SS, Zittermann A, Tenderich G, Berthold HK, Stehle P,
Koerfer R. Vitamin D supplementation improves cytokine profiles in
patients with congestive heart failure: a double-blind, randomized,
placebo-controlled trial. Am J Clin Nutr. 2006;83(4):754-759.
14. Gannagé-Yared MH, Azoury M, Mansour I, Baddoura R, Halaby G,
Naaman R. Effects of a short-term calcium and vitamin D treatment
on serum cytokines, bone markers, insulin and lipid concentrations in
healthy post-menopausal women. J Endocrinol Invest. 2003;26(8):
748-753.
15. Zittermann A, Frisch S, Berthold HK, et al. Vitamin D supplementation
enhances the beneficial effects of weight loss on cardiovascular dis-
eease risk markers. Am J Clin Nutr. 2009;89(5):1321-1327.
16. Hsia J, Heiss G, Ren H, et al. Calcium/vitamin D supplementation
and cardiovascular events. Circulation. 2007;115(7):846-854.
17. Wang L, Manson JE, Song Y, Sesso HD. Systematic review: vitamin D and calcium supplementation in prevention of cardiovascular events. *Ann Intern Med*. 2010;152(5):315-323.

18. Vacek JL, Vanga SR, Good M, Lai SM, Lakkireddy D, Howard PA. Vitamin D deficiency and supplementation and relation to cardiovascular health. *Am J Cardiol*. 2012;109(3):359-363.

19. Gepner AD, Ramamurthy R, Krueger DC, Korcarz CE, Binkley N, Stein JH. A prospective randomized controlled trial of the effects of vitamin D supplementation on cardiovascular disease risk. *PLoS One*. 2012;7(5):e36617.

20. Sun Q, Shi L, Rimm EB, et al. Vitamin D intake and risk of cardiovascular disease in US men and women. *Am J Clin Nutr*. 2011;94(2):534-542.

21. R S, AW S, D W, CM L, LT, et al. Effect of monthly high-dose vitamin D supplementation on cardiovascular disease in the vitamin D assessment study: a randomized clinical trial. *JAMA Cardiol*. 2017;2(6):608.

22. Yetley EA, Pfeiffer CM, Schleicher RL, et al. NHANES monitoring of serum 25-hydroxyvitamin D: a roundtable summary. *J Nutr*. 2010;140(11):2030S-2045S.

23. Holick MF. Vitamin D deficiency. *N Eng J Med*. 2007;357(3):266-281.

24. Rosen CJ. Vitamin D insufficiency. *N Eng J Med*. 2011;364(3):248-254.

25. Kositsawat J, Barry LC, Kuchel GA. C-reactive protein, vitamin D deficiency, and slow gait speed. *J Am Geriatr Soc*. 2013;61(9):1574-1579.

26. Bakhru A, Erlinger TP. Smoking cessation and cardiovascular disease risk factors: results from the third National Health and nutrition examination survey. *PLoS Med*. 2005;2(6):e160.

27. Eke PI, Dye BA, Wei L, et al. Update on prevalence of periodontitis in adults in the United States: NHANES 2007 to 2012. *J Periodontol*. 2015;86(5):611-622.

28. Lin MP, Ovbiagele B, Markovic D, Towfighi A. "Life’s simple 7" and long-term mortality after stroke. *J Am Heart Assoc*. 2015;4(11):e001470.

29. Bress AP, Kramer H, Khatib R, et al. Potential deaths averted and serious adverse events incurred from adoption of the SPRINT (systolic blood pressure intervention trial) intensive blood pressure regimen in the United States Clinical perspective: projections from NHANES (National Health and nutrition examination survey). *Circulation*. 2017;135(17):1617-1628.

30. Levey AS, Stevens LA, Schmid CH, Zhang YL, Castro AF, et al. A new equation to estimate glomerular filtration rate. *Ann Intern Med*. 2009;150(9):604-612.

31. Matsushita K, Mahmoodi BK, Woodward M, et al. Comparison of risk prediction using the CKD-EPI equation and the MDRD study equation for estimated glomerular filtration rate. *JAMA*. 2012;307(18):1941-1951.

32. Moore KJ, Koplev S, Fisher EA, Tabas I, Björkegren JL, et al. Macrophage trafficking, inflammatory resolution, and genomics in atherosclerosis: JACC macrophage in CVD series (part 2). *J Am Coll Cardiol*. 2018;72(18):2181-2197.

33. Wang TJ, Pancina MJ, Booth SL, et al. Vitamin D deficiency and risk of cardiovascular disease. *Circulation*. 2008;117(4):503-511.

34. Schöttker B, Jorde R, Peasey A, Thorand B, Jansen EHM, et al. Consortium on health and ageing: network of cohorts in Europe and the United States: vitamin D and mortality: meta-analysis of individual participant data from a large consortium of cohort studies from Europe and the United States. *BMJ*. 2014;348:g3656.

35. Zehnder D, Quinkler M, Eardley KS, et al. Reduction of the vitamin D hormonal system in kidney disease is associated with increased renal inflammation. *Kidney Int*. 2008;74(10):1343-1353.

36. Yin K, Agrawal DK. Vitamin D and inflammatory diseases. *J Inflamm Res*. 2014;7:69.

37. Chen Y, Zhang J, Ge X, Du J, Deb DK, Li YC. Vitamin D receptor inhibits nuclear factor κB activation by interacting with IkB kinase β protein. *J Biol Chem*. 2013;288(27):19450-19458.

How to cite this article: Li Q, Dai Z, Cao Y, Wang L. Association of C-reactive protein and vitamin D deficiency with cardiovascular disease: A nationwide cross-sectional study from National Health and Nutrition Examination Survey 2007 to 2008. *Clin Cardiol*. 2019;42:663–669. https://doi.org/10.1002/clc.23189